Grace Therapeutics’ (GRCE) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Grace Therapeutics (NASDAQ:GRCE) in a research report report published on Tuesday,Benzinga reports. They currently have a $12.00 price target on the stock. HC Wainwright also issued estimates for Grace Therapeutics’ Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.14) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.69) EPS, FY2028 earnings at $0.26 EPS and FY2029 earnings at $1.68 EPS.

Grace Therapeutics Stock Up 1.5 %

NASDAQ:GRCE opened at $3.39 on Tuesday. Grace Therapeutics has a 52-week low of $2.13 and a 52-week high of $4.97. The stock’s fifty day moving average price is $3.65. The firm has a market cap of $34.37 million, a P/E ratio of -2.92 and a beta of 1.36.

Grace Therapeutics (NASDAQ:GRCE) last announced its earnings results on Thursday, February 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. On average, equities analysts forecast that Grace Therapeutics will post -0.98 EPS for the current year.

About Grace Therapeutics

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.